An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson's ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The primary endpoint of statistically significant change ...

A recent study published in the New England Journal of Medicine conducted a trial of lixisenatide to assess its effects in early Parkinson’s disease. Study: Trial of Lixisenatide in Early Parkinson’s ...

Study: Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson’s disease. Image Credit: mozakim / Shutterstock.com Parkinson’s disease (PD) is a neurodegenerative ...

Roche and Prothena today announced topline results from the first half of their Phase 2 trial of the α-synuclein antibody prasinezumab. Results were negative on the MDS-UPDRS, the primary outcome ...

VANCOUVER – Dashing hopes raised by an earlier study, a randomized trial reported here found that caffeine didn't help improve motor function in Parkinson's disease. The CafePD trial was stopped early ...

Though wearable devices have proven to be incredibly helpful in monitoring a variety of health conditions—from diabetes to atrial fibrillation—the FDA is sending Verily back to the drawing board in ...